German Spondyloarthritis Inception Cohort
Observational · No treatment assigned · 1 site · Charite University, Berlin, Germany
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA) and Axial Psoriatic Arthritis (axPsA). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Age range not stated in the record
- Any sex
Some of the main requirements, copied from the record:
- Main inclusion Criteria:
- Patients with definite diagnosis of axial spondyloarthritis or juvenile spondyloarthritis.
- Patients with definite diagnosis of Crohn's disease.
Plus 2 more requirement(s). Only the trial team can confirm whether you qualify.
What's involved
- About 1000 participants are expected to take part.
- Start date: 2000-07.
- Main results expected around 2030-07 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Germany.
In the researchers’ words
The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately…
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA); Non-radiographic Axial Spondyloarthritis (Nr-axSpA); Axial Psoriatic Arthritis (axPsA); Acute Anterior Uveitis (AAU); Crohn Disease (CD); Ulcerative Colitis (UC) |
| Lead sponsor | Charite University, Berlin, Germany |
| Collaborators | German Federal Ministry of Education and Research; AbbVie; Amgen; Centocor, Inc.; Schering-Plough; Wyeth is now a wholly owned subsidiary of Pfizer; Berlin Institute of Health; Novartis; UCB Pharma |
| Enrollment | 1000 (estimated) |
| Start date | 2000-07 |
| Primary completion (est.) | 2030-07 |
| First posted | 2011-01-17 |
| Last updated | 2021-10-12 |
| Official title | German Spondyloarthritis Inception Cohort |
| ClinicalTrials.gov ID | NCT01277419 |
Interventions
- None listed
Full eligibility criteria (from the record)
Main inclusion Criteria: * Patients with definite diagnosis of axial spondyloarthritis or juvenile spondyloarthritis. * Patients with definite diagnosis of Crohn's disease. * Patients with definite diagnosis of acute anterior uveitis. * Patients with definite diagnosis of psoriatic arthritis with axial involvement.
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Charité - Universitätsmedizin Berlin | Berlin | Germany | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.